When assessing Covid-19 pathway for patients with no underlying chronic respiratory condition, there is no evidence to support use of OPEP pre-infection. Post-infection, there is limited evidence. For example, if the patient has been ventilated or immobile for an extended period of time there is some adjacent evidence associated with reduced post-operative complications when using OPEP. As a treatment for Covid-19, OPEP therapy is not proven, and the infection is not typically associated with excess mucus, however a couple of references advocate the use of OPEP as required in those instances where airway clearance may be beneficial. CONCLUSIONS: Management of Covid-19 is a complex and not fully understood area. Patients with a pre-existing chronic respiratory condition exhibiting excess mucus will likely benefit from use of an appropriate OPEP device. The evidence is less clear for those patients without pre-existing respiratory conditions, with further evidence beneficial to support OPEP in treatment and post infection rehabilitation.